Application number	Application type	Number of applications	Performance	Target days	Average days
1	Major timetable (National) New MRLs. All other MA applications (excl. MAPI and Copycats)	44	100%	180.0	18
2	Standard timetable (National Type II variations. New MA - MAPIs and Copycats. New VHRs)	45	100%	120.0	11
3	Shortened timetable (National Renewals (MA and VHR) Type IB variations. New ATC (type B). Out of Scope MRLs)	302	99.7%	60.0	8
4	Minor timetable (National) Type IA variations. Administrative Type IB variations. New ATC (Type A/S). ATC variations and renewals.	564	98.6%	30.0	19
5	Parallel Assessment with EU Procedures	780	100%	-	15
6	Shared Assessment with International Partners	0	-	-	0
7	Batch timetable (National) specific Batch Control	62	98.4%	20.0	4
8	Autogenous Vaccines. New & Variations	7	100%	45.0	41

Published Standard Number 1 – Applications (National)

Published Standard Number 1 – Applications (Other)

Application number	Application Type	Number of applications	Performance
9	Mock-up period completed within 20 days (or up to 40 days for parallel applications involving different QRD sources)	741	97%
10	Validation	1619	100%
11	Issue of authorised documentation	2232	100%

Published Standard Number 1 – Applications (European - NI)

Application number	Application Type	Number of applications	Performance
12	New Decentralised (DCP)	43	100%
13	New Mutual Recognition (MRP)	2	100%
14	MRP Variations (Type IB & II) and Renewals	338	100%

Application number	Application type	Total number	Performance
15	Publishing Summary of Product Characteristics (SPCs)	98	99%
16	Publishing Public Assessment Reports (PuARs)	58	100%
17	Updating PuARs	7	100%

Published Standard Number 2 – Public Assessment Reports

Published Standard Number 3 – Quality of Documentation

Applicatio	n number	Application type	Number of applications	Performance
18	Unreturr	ed Documents	3719	97.4%

Published Standard Number 4 – Product Defects

Task number	Task	Number of tasks	Performance	Target Days	Average Days
19	Product Defects reports	47	100%		
	High risk <5 days	2	-		
	Low risk <10 days	45	-		

Published Standard Number 5 – Import, Export and Batch Release Schemes

Application number	Application Type	No of Apps	Performance	Target Days	Average Days
20	Applications for new pharmaceutical products	80	100%	15	-
21	Applications for new Immunological products	19	94.7%	25	-
22	Applications for previously imported products	295	99.3%	15	-
23	All other urgent applications Urgent Non Urgent	546 0 546	99.6%	- 2 10	-
24 25 26	Instant Import Certificates Export Batch Release	31,545 282 2623	- 100% 99.8%	- 10 10	- 6.0 3.2

Published Standard Number 6 – Pharmacovigilance

Task number	Task	No.	Performance
27	Human, Animal & Environmental AERs	8199	99.9%
28	PSURs	1452	100%
29	Inspections	22	100%

Task number	Task	No.	Performance	Target Days
30	Inspections within 3 years (GMP)	23	100%	-
	Within 5 years (GDP) of last inspection	27	Joint with above	-
31	Inspection Deficiency Reports	48	100%	30.0
32	(GMP) Certificates or (GDP) final reports sent	51	100%	90.0
33	Approval of new Feed business operators and SQP retailer sites	54	100%	45.0
34	Final inspection report to Feed business operators and SQP retailers	320	99.3%	30.0

Published Standard Number 7– Inspections

Our inspection procedures enable us to extend our GMP inspections beyond 3 years and our GDP inspections beyond 5 years where there are exceptional circumstances, provided a documented risk-assessment is carried out. Risk-assessments have been conducted for all sites where it has not been possible for us to inspect them within 3 years due to covid-19 related restrictions.

Key:

100% Excellent

>97% - 100% Excellent, but some targets missed

92% - 97% Effective

< 91% Ineffective

Additional information

The VMD continuously monitors all targets and puts in place countermeasures, where possible, to ensure targets are met.

However, sometimes a performance standard may fall into the effective or ineffective category and there are a number of reasons why this may happen, for example high volume of applications, staff resource, complexity of applications requiring additional input and so on.